Teresa Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Teresa Zhao has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- David Arthur Stroud
Department of Biochemistry and Pharmacology and Bio21 Molecular Science and Biotechnology Institute, 30 Flemington Road. The University of Melbourne, Victoria 3010 Australia; Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia; Victorian Clinical Genetics Services, Royal Children's Hospital, Melbourne, VIC, 3052, Australia
5 shared publications - John Christodoulou
Murdoch Children’s Research Institute, Melbourne, Australia
5 shared publications - David R. Thorburn
Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Australia
3 shared publications - Andrew Paul Fennell
Monash Genetics, Monash Health, Melbourne, Australia
2 shared publications - Elaine Zhang
Brain and Mitochondrial Research Group Murdoch Children's Research Institute Melbourne Victoria Australia
2 shared publications - Katrina M. Bell
Murdoch Children's Research Institute, Melbourne, Australia
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Establishing The Australian Undiagnosed Diseases Network (UDN-Aus); Australia’s first national rare disease diagnostic network
Background: An estimated 1 in 12 individuals across the world have a rare disease. The Undiagnosed Diseases Network International (UDNI) recommend Undiagnosed Disease Programs (UDPs) as the best approach to facilitate diagnosis and support for those affected. The Australian Undiagnosed Diseases Network (UDN-Aus) was the first National Australian UDP initiative funded by the Medical Research Future Fund’s Genomics Health Futures Mission (MRFF2007567). Aims: UDN-Aus brings together an unprecedented national collaborative network for rare disease, aiming to improve the rate of genomic diagnoses for those with undiagnosed rare genetic conditions, enabling precise, personalised care to individuals throughout Australia. Methods: The research program recruited Australians who were seen through a clinical genetics service and remained undiagnosed following clinically available genomic testing. This paper outlines the approach taken to establish a national research project at 12 clinical recruitment sites. The methods detail the funding, aims, governance, study design, population and participation process, health economic research and preliminary results, and recommendations for future sustainability and implementation. Results: The study was approved by the Royal Children’s Hospital Human Research Ethics Committee on 19 November 2021 (RCH79712), with relevant site-specific approvals at local recruitment sites. Key benefits and barriers in the establishment of UDN-Aus are outlined. Conclusion: The successful establishment of this program required several components, including meaningful and ongoing community and stakeholder engagement, strategic appointment of key operational staff, and a tailored approach to facilitate more equitable enrolment. It also highlighted several crucial areas for consideration to ensure future sustainable implementation of a national UDP. These include continued investment in Australia’s national genomic data transfer policy and infrastructure, and research ethics and governance procedures imperative for the sustainable delivery of genomic research for rare disease.
- 5 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
Open AccessEstablishing The Australian Undiagnosed Diseases Network (UDN-Aus); Australia’s first national rare disease diagnostic network
Background: An estimated 1 in 12 individuals across the world have a rare disease. The Undiagnosed Diseases Network International (UDNI) recommend Undiagnosed Disease Programs (UDPs) as the best approach to facilitate diagnosis and support for those affected. The Australian Undiagnosed Diseases Network (UDN-Aus) was the first National Australian UDP initiative funded by the Medical Research Future Fund’s Genomics Health Futures Mission (MRFF2007567). Aims: UDN-Aus brings together an unprecedented national collaborative network for rare disease, aiming to improve the rate of genomic diagnoses for those with undiagnosed rare genetic conditions, enabling precise, personalised care to individuals throughout Australia. Methods: The research program recruited Australians who were seen through a clinical genetics service and remained undiagnosed following clinically available genomic testing. This paper outlines the approach taken to establish a national research project at 12 clinical recruitment sites. The methods detail the funding, aims, governance, study design, population and participation process, health economic research and preliminary results, and recommendations for future sustainability and implementation. Results: The study was approved by the Royal Children’s Hospital Human Research Ethics Committee on 19 November 2021 (RCH79712), with relevant site-specific approvals at local recruitment sites. Key benefits and barriers in the establishment of UDN-Aus are outlined. Conclusion: The successful establishment of this program required several components, including meaningful and ongoing community and stakeholder engagement, strategic appointment of key operational staff, and a tailored approach to facilitate more equitable enrolment. It also highlighted several crucial areas for consideration to ensure future sustainable implementation of a national UDP. These include continued investment in Australia’s national genomic data transfer policy and infrastructure, and research ethics and governance procedures imperative for the sustainable delivery of genomic research for rare disease.
- Open Access
- 11 May 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (10) , 2338-2344
Unraveling a Diagnostic Enigma: A TECPR2 Case Solved Through Multi‐Omic Genomics
TECPR2 is a key regulator of autophagy, encoded by the TECPR2 gene. Pathogenic variants in this gene have been linked to a rare hereditary sensory and autonomic neuropathy with intellectual disability (HSAN9). We report a teenage female with a syndromic intellectual disability disorder associated with neuromuscular abnormalities. Multi‐omics analysis including genomics, transcriptomics, and proteomics, together with muscle biopsy from the affected individual, were used in this clinical case. Through trio exome sequencing we identified two heterozygous variants in the TECPR2 gene, NM_014844.4: c.480G>A; p.(Gln160=) and c.2846C>A; p.(Ala949Glu). Both were classified as variants of uncertain significance due to the lack of supporting evidence for pathogenicity. Subsequent long‐read sequencing phased the variants and confirmed they were in trans . Additional functional studies using RNAseq and proteomics analyses verified the pathogenicity of the variants. This case study demonstrated the value of a multi‐omics assisted analysis, which complemented the traditional phenotype‐first approach in reaching a definitive clinical diagnosis.
- 11 May 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (10) , 2338-2344
Open AccessUnraveling a Diagnostic Enigma: A TECPR2 Case Solved Through Multi‐Omic Genomics
TECPR2 is a key regulator of autophagy, encoded by the TECPR2 gene. Pathogenic variants in this gene have been linked to a rare hereditary sensory and autonomic neuropathy with intellectual disability (HSAN9). We report a teenage female with a syndromic intellectual disability disorder associated with neuromuscular abnormalities. Multi‐omics analysis including genomics, transcriptomics, and proteomics, together with muscle biopsy from the affected individual, were used in this clinical case. Through trio exome sequencing we identified two heterozygous variants in the TECPR2 gene, NM_014844.4: c.480G>A; p.(Gln160=) and c.2846C>A; p.(Ala949Glu). Both were classified as variants of uncertain significance due to the lack of supporting evidence for pathogenicity. Subsequent long‐read sequencing phased the variants and confirmed they were in trans . Additional functional studies using RNAseq and proteomics analyses verified the pathogenicity of the variants. This case study demonstrated the value of a multi‐omics assisted analysis, which complemented the traditional phenotype‐first approach in reaching a definitive clinical diagnosis.
- 22 October 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (3) , 632-641
Functional Characterization of a Novel GPC3 Missense Variant in Simpson–Golabi–Behmel Syndrome
Simpson–Golabi–Behmel syndrome 1 (SGBS1) is a rare X‐linked recessive condition characterized by overgrowth and multiple congenital anomalies. SGBS1 is caused by damaging variants in the Glypican‐3 ( GPC3 ) gene. The GPC3 protein plays a crucial role in cellular signaling processes including cell growth, embryogenesis, and differentiation. Functional maturation of GPC3 occurs via several steps of post‐translational modification (PTM) and processing to enable its transport to, and anchorage on, the plasma membrane. GPC3 positively modulates the canonical Wnt signaling pathways, while negatively regulating the Hedgehog signaling pathways. Loss‐of‐function is the underlying mechanism of disease for SGBS1, with a minority of reported pathogenic variants being missense substitutions. We report a family with four affected individuals in whom a novel GPC3 missense variant was identified via exome sequencing: NM_004484.3: c.695C>A; p.(Ala232Asp). The variant segregated with disease in the family, and functional studies conducted using HEK293T cells demonstrate a distinct mis‐localization of the mutant GPC3 protein, thereby supporting the pathogenicity of this novel missense variant. These findings allowed for an upgraded classification of the missense variant from a variant of uncertain significance to that of likely pathogenic.
- 22 October 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (3) , 632-641
Functional Characterization of a Novel GPC3 Missense Variant in Simpson–Golabi–Behmel Syndrome
Simpson–Golabi–Behmel syndrome 1 (SGBS1) is a rare X‐linked recessive condition characterized by overgrowth and multiple congenital anomalies. SGBS1 is caused by damaging variants in the Glypican‐3 ( GPC3 ) gene. The GPC3 protein plays a crucial role in cellular signaling processes including cell growth, embryogenesis, and differentiation. Functional maturation of GPC3 occurs via several steps of post‐translational modification (PTM) and processing to enable its transport to, and anchorage on, the plasma membrane. GPC3 positively modulates the canonical Wnt signaling pathways, while negatively regulating the Hedgehog signaling pathways. Loss‐of‐function is the underlying mechanism of disease for SGBS1, with a minority of reported pathogenic variants being missense substitutions. We report a family with four affected individuals in whom a novel GPC3 missense variant was identified via exome sequencing: NM_004484.3: c.695C>A; p.(Ala232Asp). The variant segregated with disease in the family, and functional studies conducted using HEK293T cells demonstrate a distinct mis‐localization of the mutant GPC3 protein, thereby supporting the pathogenicity of this novel missense variant. These findings allowed for an upgraded classification of the missense variant from a variant of uncertain significance to that of likely pathogenic.
- Open Access
- 31 March 2025
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-13
Review: Utility of mass spectrometry in rare disease research and diagnosis
- 31 March 2025
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-13
Open AccessReview: Utility of mass spectrometry in rare disease research and diagnosis
- Open Access
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 5485987
CHD8 Variant and Rett Syndrome: Overlapping Phenotypes, Molecular Convergence, and Expanding the Genetic Spectrum
Rett syndrome (RTT) is a rare, X‐linked, severe neurodevelopmental disorder, predominantly associated with pathogenic variants in the methyl‐CpG‐binding protein‐2 (MECP2) gene, with an increasing number of atypical RTT or RTT‐like individuals having pathogenic variants in other genes, such as cyclin‐dependent kinase‐like 5 (CDKL5) or forkhead box G1 (FOXG1). However, ~20% of individuals with a clinical diagnosis of RTT remain genetically undiagnosed, highlighting the importance of ongoing genomic and functional studies to expand the genetic spectrum of RTT. We present a female who was born to healthy nonconsanguineous parents and presented with severe intellectual disability, macrocephaly, ataxia, absent speech, and poor eye contact. The affected individual was clinically diagnosed with atypical RTT, but genetic testing showed no pathogenic variants in MECP2, CDKL5, or FOXG1. Singleton whole genome sequencing was conducted, which identified a heterozygous stop–gain variant [NM_001170629.2: c.5017C>T, p.(Arg1673 ∗)], in the chromodomain‐helicase‐DNA‐binding protein 8 (CHD8) gene. Variant curation revealed its absence in unaffected populations, in silico predictions of pathogenicity, and an existing association with intellectual developmental disorder with autism and macrocephaly (IDDAM) (OMIM #615032). In vitro functional analyses, including Western blots, quantitative reverse transcription polymerase chain reaction (qRT‐PCR), and proteomic analyses, demonstrated a significant reduction of the CHD8 transcript and two CHD8 protein isoforms in the proband’s skin fibroblasts relative to control fibroblasts. Additionally, proteomic analysis indicated a significant reduction of the MeCP2 protein, indicating a possible molecular link between CHD8 and MeCP2 and thus clinically between IDDAM and RTT. As the affected individual’s phenotype is consistent with atypical RTT, our results suggest that CHD8 could be considered in the expanding genetic spectrum of atypical RTT, which may assist the diagnosis of other MECP2‐negative RTT individuals.
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 5485987
Open AccessCHD8 Variant and Rett Syndrome: Overlapping Phenotypes, Molecular Convergence, and Expanding the Genetic Spectrum
Rett syndrome (RTT) is a rare, X‐linked, severe neurodevelopmental disorder, predominantly associated with pathogenic variants in the methyl‐CpG‐binding protein‐2 (MECP2) gene, with an increasing number of atypical RTT or RTT‐like individuals having pathogenic variants in other genes, such as cyclin‐dependent kinase‐like 5 (CDKL5) or forkhead box G1 (FOXG1). However, ~20% of individuals with a clinical diagnosis of RTT remain genetically undiagnosed, highlighting the importance of ongoing genomic and functional studies to expand the genetic spectrum of RTT. We present a female who was born to healthy nonconsanguineous parents and presented with severe intellectual disability, macrocephaly, ataxia, absent speech, and poor eye contact. The affected individual was clinically diagnosed with atypical RTT, but genetic testing showed no pathogenic variants in MECP2, CDKL5, or FOXG1. Singleton whole genome sequencing was conducted, which identified a heterozygous stop–gain variant [NM_001170629.2: c.5017C>T, p.(Arg1673 ∗)], in the chromodomain‐helicase‐DNA‐binding protein 8 (CHD8) gene. Variant curation revealed its absence in unaffected populations, in silico predictions of pathogenicity, and an existing association with intellectual developmental disorder with autism and macrocephaly (IDDAM) (OMIM #615032). In vitro functional analyses, including Western blots, quantitative reverse transcription polymerase chain reaction (qRT‐PCR), and proteomic analyses, demonstrated a significant reduction of the CHD8 transcript and two CHD8 protein isoforms in the proband’s skin fibroblasts relative to control fibroblasts. Additionally, proteomic analysis indicated a significant reduction of the MeCP2 protein, indicating a possible molecular link between CHD8 and MeCP2 and thus clinically between IDDAM and RTT. As the affected individual’s phenotype is consistent with atypical RTT, our results suggest that CHD8 could be considered in the expanding genetic spectrum of atypical RTT, which may assist the diagnosis of other MECP2‐negative RTT individuals.